ES3067563T3 - Pulsative gnrh administration for use in treating cognitive disorders - Google Patents

Pulsative gnrh administration for use in treating cognitive disorders

Info

Publication number
ES3067563T3
ES3067563T3 ES20722577T ES20722577T ES3067563T3 ES 3067563 T3 ES3067563 T3 ES 3067563T3 ES 20722577 T ES20722577 T ES 20722577T ES 20722577 T ES20722577 T ES 20722577T ES 3067563 T3 ES3067563 T3 ES 3067563T3
Authority
ES
Spain
Prior art keywords
gnrh
mice
cognitive
olfactory
ts65dn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20722577T
Other languages
English (en)
Spanish (es)
Inventor
Vincent Prevot
Andrea Messina
Paolo Giacobini
Valérie Leysen
Lozano Maria Manfredi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Lille
Université de Lille
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Regional Universitaire de Lille CHRU
Université de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Regional Universitaire de Lille CHRU, Université de Lille filed Critical Institut National de la Santé et de la Recherche Médicale
Application granted granted Critical
Publication of ES3067563T3 publication Critical patent/ES3067563T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES20722577T 2019-04-30 2020-04-29 Pulsative gnrh administration for use in treating cognitive disorders Active ES3067563T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305550 2019-04-30
PCT/EP2020/061943 WO2020221821A1 (en) 2019-04-30 2020-04-29 Pulsative gnrh administration for treating cognitive disorders

Publications (1)

Publication Number Publication Date
ES3067563T3 true ES3067563T3 (en) 2026-05-22

Family

ID=66625872

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20722577T Active ES3067563T3 (en) 2019-04-30 2020-04-29 Pulsative gnrh administration for use in treating cognitive disorders

Country Status (6)

Country Link
US (1) US20220202895A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962494B1 (cg-RX-API-DMAC7.html)
JP (1) JP7779739B2 (cg-RX-API-DMAC7.html)
DK (1) DK3962494T3 (cg-RX-API-DMAC7.html)
ES (1) ES3067563T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020221821A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022136417A1 (en) 2020-12-22 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Pulsative gnrh administration for treating food intake related disorders
AU2023332041A1 (en) 2022-09-02 2025-02-20 Leibniz-Institut Für Immuntherapie (Lit) THERAPEUTIC USE OF THE miR155 SNP rs377265631

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158683B1 (de) 1984-04-14 1988-10-05 Ferring Biotechnik GmbH Vorrichtung zum intermittierenden Applizieren flüssiger Arzneimittel
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5013293A (en) 1987-05-28 1991-05-07 Drug Delivery Systems Inc. Pulsating transdermal drug delivery system
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
WO2007041386A2 (en) 2005-09-30 2007-04-12 Vyteris, Inc. Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch
WO2014110549A1 (en) * 2013-01-14 2014-07-17 The General Hospital Corporation Methods and assays relating to rnf216
WO2014179139A2 (en) * 2013-04-30 2014-11-06 Albert Einstein College Of Medicine Of Yeshiva University TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK-β/NF-κΒ INHIBITION
WO2017182580A1 (en) 2016-04-20 2017-10-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception
CN108837143B (zh) * 2018-09-29 2022-03-01 南华大学 曲普瑞林的应用

Also Published As

Publication number Publication date
JP7779739B2 (ja) 2025-12-03
US20220202895A1 (en) 2022-06-30
DK3962494T3 (da) 2026-04-07
WO2020221821A1 (en) 2020-11-05
EP3962494A1 (en) 2022-03-09
JP2022533011A (ja) 2022-07-21
EP3962494B1 (en) 2026-03-04